Barbour County. West Virginia Board of Pharmacy Prescription Opioid Problematic Prescribing Indicators County Report Barbour County

Similar documents
Putnam County. West Virginia Board of Pharmacy Prescription Opioid Problematic Prescribing Indicators County Report

Mingo County. West Virginia Board of Pharmacy Prescription Opioid Problematic Prescribing Indicators County Report

Kanawha County. West Virginia Board of Pharmacy Prescription Opioid Problematic Prescribing Indicators County Report

Pocahontas County. West Virginia Board of Pharmacy Prescription Opioid Problematic Prescribing Indicators County Report

Greenbrier County. West Virginia Board of Pharmacy Prescription Opioid Problematic Prescribing Indicators County Report

Targeting an Epidemic: Opioid Prescribing Patterns by County in New York State

The Epidemiology of Opioid Abuse. Thomas Dobbs, MD, MPH Mississippi State Department of Health

The Epidemiology of Opioid Abuse Thomas Dobbs, MD, MPH 6/30/2017

Opioid Overdose in Oregon Report to the Legislature

Addressing the Opioid Epidemic in Tennessee

Blue Cross of Idaho Addresses State s Opioid Issue

Opioid Use and Other Trends

Strategic Prevention Framework for Prescription Drugs

New Mexico Prescription Monitoring Program Data Report

Identification of Specific Drugs and Drug Diversion in Drug Overdose Fatalities

Epi Data Tables. Benzodiazepines in New York City. Data Tables

Opioid Data for Local Governments in North Carolina

U.S. Counties Vulnerability to Rapid Dissemination of HIV/HCV Infections Among People Who Inject Drugs

OHIO S PRESCRIPTION DRUG OVERDOSE EPIDEMIC:

Pennsylvania Prescription Drug Monitoring Program Trends,

April 26, New Mexico Board of Pharmacy Prescription Monitoring Program (PMP) New Mexico Board of Pharmacy Prescription Monitoring Program (PMP)

North Carolina, like the rest of the nation, has been experiencing

Interstate Variation in Prescribing of Opioid Pain Relievers and Benzodiazepines Karin A. Mack, PhD Associate Director for Science

New Mexico Board of Pharmacy Prescription Monitoring Program (PMP)

Opioid epidemic and PEHP

Mental and Behavioral Health

HHS Priorities and Actions to Support Treatment for Those with Opioid Use Disorder

The Morbidity and Mortality of Kansas Drug Epidemic

Academic Medical School: Implementing Curriculum in Chronic Pain and Opioid Misuse. Jill M Williams, MD

Drug Overdose in New Mexico

Prescription Opioid Overdose in Oregon: A public health perspective

Opioid Abuse in Iowa Rx to Heroin. Iowa Governor s Office of Drug Control Policy January 2016

Prescription Drug Monitoring Program Update. Rebecca R. Poston, BPharm., MHL Program Manager August 26, 2017

The Opioid Epidemic: HHS Response

The Opioid Epidemic: Overdose Data in NYC

Using the NC Controlled Substances Reporting System to Identify Providers Manifesting Unusual Prescribing Practices

Harold Rogers Update Melissa McPheeters, PhD, MPH

Opioids: What You Should Know About Opioid Prescribing. Denis G. Patterson, DO Nevada State Medical Association October 19, 2016

CDC s Efforts to End the Opioid Epidemic

NM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT THIRD QUARTER OF 2018 (2018Q3)

NM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT FOURTH QUARTER OF 2017 (2017Q4)

OPIOID OVERDOSE EPIDEMIC: What Healthcare Providers Need to Know

The Opioid Epidemic: The State of the State

Opioid Prescription and Illicit Drug Overdoses: On the Rise

Opioid Abuse and Prescribing. Dr. Mitchell Mutter Director of Special Projects

Scott Kirby, M.D, Medical Director, North Carolina Medical Board. Chris Ringwalt, Dr.P.H., Senior Scientist, UNC Injury Prevention Research Center

PRESCRIBING GUIDELINES

Opioid Review and MAT Clinic CDC Guidelines

Responding to the Prescription Opioid and Heroin Crisis: An Epidemic of Addiction

Opioid Epidemic as it Relates to Counties

Figure 1. National Drug Overdose Deaths Number Among All Ages, by Gender,

The Devastating Toll of Tobacco

using analytics to identify and strategically manage patient opioid abuse

Medicare Part D Prescription Opioid Policies for 2019 Information for Pharmacists

Prescription Drug Abuse and Heroin: Impact on Oregon s Youth and Young Adults

OPIOIDS IN JACKSON COUNTY A PUBLIC HEALTH PERSPECTIVE OPIOID AWARENESS COUNTY LEADERSHIP FORUM SHELLEY CARRAWAY, HEALTH DIRECTOR DATE

INTER-AMERICAN DRUG ABUSE CONTROL COMMISSION C I C A D

NM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT THIRD QUARTER OF 2017 (2017Q3)

Drug Overdose Deaths St. Louis County, Missouri

PRESCRIPTION DRUG MONITORING PROGRAM

Data-Driven Multidisciplinary Approaches to Reduce Prescription Drug Abuse in Kentucky

Injecting in Vain Elizabeth Marshall SOC/CRM 496: Public Sociology & Criminology Practicum (Spring 2018)

Youth Opioid Study: Attitudes and Usage Young Adults Ages 18 to 24 in the United States

Michael M. Miller, MD, FASAM, FAPA

6/6/2017. First Do No Harm SECTION 1 THE OPIOID CRISIS. Implementing an Opioid Stewardship Program in a HealthCare System OBJECTIVES

Ranked in the top 10% in: -Low percent of adults reporting fair or poor health

Opioid Use and Misuse: History, Trends, And The Oregon Opioid Initiative

A National Perspective on the Abuse and Diversion of Prescription Drugs

Standard of Practice for Prescribing Opioids (Excluding Cancer, Palliative, and End-of-Life Care)

Population Health Vital Statistics Brief:

PDMP Tools to Identify Red Flag Situations

Tri-County Region Opioid Trends Clackamas, Multnomah, and Washington, Oregon. Executive Summary

Responding to the Prescription Opioid and Heroin Crisis: An Epidemic of Addiction

Opioid Crisis: HHS Strategy and Advancing Pain Management

Oregon s PDMP: An epidemiological assist tool

Assessing Opioid Misuse and Overdose Using Prescription Drug Monitoring Programs (PDMP) and Other Data Sources

REAL TIME MONITORING OF PRESCRIPTION MEDICINES BEING A HEALTHY STATE

Opioids drive continued increase in drug overdose deaths

The STOP Measure. Safe and Transparent Opioid Prescribing to Promote Patient Safety and Reduced Risk of Opioid Misuse FEBRUARY 2018

The Oregon Opioid Initiative. State Pain & Opioid Conference Prescription Drug Monitoring May 2018 Lisa Millet, Public Health Division

Opioid Abuse. in Rural Minnesota. County Farm Bureau Resource Guide

Summit County Public Health

Controlled Substance Prescribing Trends and Odds of Drug Overdose Death

The Impact of the U.S. Drug Enforcement Agency Schedule Changes for Hydrocodone and Tramadol on California Prescriptions Patterns

Prescription Drug Abuse National Perspective

Online Appendix. Supply-Side Drug Policy in the Presence of Substitutes: Evidence from the Introduction of Abuse-Deterrent Opioids

Understanding the Opiate Epidemic

Safe Prescribing of Drugs with Potential for Misuse/Diversion

Battling Opioid Addiction: Public Policy and Healthcare Strategies for an Epidemic

A Different Kind of Drug War. CINDY SANDERS Posted: Thursday, April 5, :07 pm. Providers Focus on Prescription Drug Addiction, Abuse

4/12/2018. Opioid Addiction and Prescribing. Disclosure Statement of Financial Interest

Drug-Related Deaths in Yolo County,

WHAT YOU NEED TO KNOW TO ABOUT AB 474

Montgomery County Poisoning Death Review:

Key points. o Potential for nonmedical use, abuse, and diversion of new products

University of Pittsburgh

Article #2 Prescription Drug Overdose CDC: Centers for Disease Control and Prevention. Understanding the Epidemic

Opioid Deaths Quadruple Since 1999

9/5/2011. Outline. 1. Past and Current Trends re: RX Abuse 2. Diversion Methods 3. Regulatory Reporting Requirements 4. Q/A

Section I. Short-acting opioid Prior Authorization Criteria

Transcription:

County West Virginia Board of Pharmacy Prescription Opioid Problematic Prescribing Indicators County Report County The West Virginia Violence and Injury Prevention Program ( VIPP), in collaboration with the West Virginia Board of Pharmacy and the West Virginia University Injury Control Research Center (ICRC), under the direction of the Centers for Disease Control and Prevention (CDC), are working to address prescription drug misuse, diversion, and overdose within the state of West Virginia. Prescription drug overdose continues to be a major issue in West Virginia. In 2016, over 880 people died in association with drug misuse (including prescription and illicit drugs). This is nearly three times the national average. To help combat this epidemic, CDC provided specific indicators to identify high-risk areas within the state to allow for intervention and community education. The Controlled Substance Act, signed into law in 1970 by President Richard Nixon, is a federal drug policy that established regulations in the manufacturing and distribution of controlled substances. Controlled substances are categorized into five different classes or schedules, known as schedule I, II, III, IV, and V. Schedule I drugs are considered the most harmful and have the greatest potential for abuse and have no current accepted medical use. Drugs in this class include but are not limited to, Heroin, Cocaine, and Marijuana. Schedule II drugs also have a high potential for abuse but have current accepted medical use. Schedules III-V all have potential for abuse but that potential decreases. The Controlled Substance Act also requires that all entities and individuals who manufacture, distribute, import or export controlled substances be registered under the law. Opioids can be classified as either schedule II, III, or IV. CDC has given VIPP six specific indicators to assist in measuring prescription use. These six indicators include: 1) Number and rate of opioid analgesics (pain relievers), 2) Percent of patients receiving more than an average daily dose of 90 morphine milligram equivalents (MMEs), 3) Rate of multiple provider episodes for prescription opioids, which is patients who have seen 5 or more prescribers and have been to 5 or more pharmacies within a six-month period, 4) Percent of patients prescribed long-acting/extended release opioids among opioid-naïve patients, i.e. patients who have not taken opioid analgesics in 60 days, 5) Percent of patient prescription days with overlapping opioid prescriptions, and 6) Percent of patient prescriptions days with overlapping opioid and benzodiazepine prescriptions. Source: https://www.cdc.gov/drugoverdose/media/index.html West Virginia Board of Pharmacy October 2017 1

County Below is some general demographic information for the county and the state. Table 1. Figure 1. Demographic Data 2015 Population 16,723 1,844,128 Race White 96.90% 93.60% Black 0.80% 3.20% Other 2.30% 3.20% Median age 40.8 41.6 Median household income 36,351 41,576 Income below federal poverty level High school graduate or higher 15.10% 13.10% 79.00% 84.40% Percent of Population 20% 18% 16% 14% 12% 10% 8% 6% 4% 2% 0% Population by Age Group, 2015 Source: US Census Bureau, 2014 population estimates Mortality Data Deaths related to drug overdose have increased substantially since 2001. In fact, the number of deaths in 2016 was nearly five times the number of deaths in 2001. These deaths include overdoses related to any drug. The percent of overdose deaths involving Fentanyl have also increased considerably. There was a slight increase from 2001 to 2003 then it began to drop. However, between 2014 and 2016, the percentage increased to nearly 40%, almost eight times higher than in 2001. Figure 2. Figure 3 Number of Drug Overdose Deaths,, 2001-2016 Percent of Overdose Deaths Involving Fentanyl,, 2001-2016 Number of Deaths 1000 800 600 400 200 0 174 820 Percent of Deaths 45.0 4 35.0 3 25.0 2 15.0 5.0 5.2 39.5 Source: West Virginia Health Statistics Center, Vital Statistics System West Virginia Board of Pharmacy October 2017 2

County Drug overdose death rates per 100,000 population in West Virginia are significantly higher than the U.S. rates for all years. There has been a 369% increase in the rate of drug overdose deaths in West Virginia from 2001 to 2016, compared to only a 149% increase in the U.S. during the same years. Figure 4. Drug Overdose Deaths, versus US, 2001-2016 Rate per 100,000 population 5 45.0 4 35.0 3 25.0 2 15.0 5.0 6.8 46.9 16.9 US Source: West Virginia Health Statistics Center, Vital Statistics System Drug overdose death rates per 100,000 population in County are below the state rate. The graphs below show the rates of overdose death for County compared to West Virginia as a whole for both drugs, overall, and opioids, specifically. Figure 5. Figure 6. Rate of Deaths 1 6 5 4 3 2 County Rank 1 Rate of All Drug Overdose Deaths per 100,000 Population, County and, 2014-2016 34.0 6.0 39.9 12.0 48.0 5.9 48 42 48 Rate of Deaths 5 4 3 2 County Rank Rate of Opioid Drug Overdose Deaths per 100,000 Population, County and, 2014-2016 29.7 6.0 34.4 12.0 40.6 5.9 46 40 44 Source: West Virginia Health Statistics Center, Vital Statistics System 1 Each county is ranked from 1 to 55, where a rank of 1 is assigned to the County with the highest rate or percentage as indicated and a 55 to the County with the lowest rate or percentage. West Virginia Board of Pharmacy October 2017 3

County Indicators Indicator 1: Number and rate of opioid analgesics per 1,000 state residents This indicator includes all opioid prescriptions that are classified as either II, III or IV. The figures below show the total number of opioid prescriptions for County and the rate per 1,000 population compared to the state. Census data was used to obtain demographic information and population sized. Figure 7. Figure 8. Number of Opioid Analgesics Dispensed, County, 2014-2016 17,183 17,341 Rate of Opioid Analgesics per 1,000 Population, County and, 2014-2016 1024.9 1104.2 1098.0 1038.1 1040.1 960.2 16,161 County Rank 28 30 30 This indicator is important because it provides information about prescription opioid use for each county. These data will help determine areas where high prescribing/dispensing are occurring around the state and allow for education on responsible opioid prescribing. High rates of opioid dispensing mean large quantities of drug that is out in the community. There was an overall decrease in the rate of opioids being prescribed in County and the state from 2014-2016. Compared to all other counties, County ranked near the middle. West Virginia Board of Pharmacy October 2017 4

County Indicator 2: Percent of patients receiving more than an average daily dose of > 90 morphine milligram equivalents (MME). This indicator shows the total average daily dose of MMEs that a patient is taking. It includes all opioid prescriptions that are classified as either II, III or IV. MMEs are used as a measure to describe the potency of an opioid. Calculating MMEs is important to determine which patients may be at risk for an overdose. The figure below shows the percent of patients with greater than an average daily dose of 90 MMEs in County compared to the state during 2014-2016. Figure 9. Percent of Patients 18.0 16.0 14.0 12.0 8.0 6.0 4.0 2.0 Percent of Patients Receiving more than an Average Daily Dose of 90 MMEs, County and, 2014-2016 11.9 11.5 11.4 11.8 10.8 9.6 County Rank 26 29 35 This indicator is important because it provides information for prescribers about how much morphine equivalent drug the patient is receiving. MMEs help determine the amount of morphine an opioid dose is equal to when prescribed, often used as a gauge of the abuse and overdose potential of the amount of opioid that is being given at a particular time. It is also a useful tool to identify high-burden areas in the state, which is important for public health surveillance at a county level. County was overall slightly lower than the state and decreased during 2014-2016. Compared to all other counties, County ranked near the middle. West Virginia Board of Pharmacy October 2017 5

County Indicator 3: Rate of multiple provider episodes for prescription opioids (5 or more prescribers and 5 or more pharmacies in a 6-month period) per 100,00 residents. This indicator shows the rate of patients who went to 5 or more prescribers and 5 or more pharmacies within a 6-month period, or multiple provider episode (MPE). The rate is calculated per 100,000 population. It includes all opioid prescriptions that are classified as either II, III or IV. Figure 10. Rate of MPE's 12.0 8.0 6.0 4.0 2.0 Rate of Multiple Provider Episodes (MPE) for Prescription Opioids per 100,000 Population, County and, 2014-2016 9.2 6.0 6.8 3.3 County 41 51 46 Rank This indicator is important because provides valuable information on prescription filling behaviors. Patients who receive prescriptions from more than five doctors and who fill at more than five pharmacies are at greater risk of drug overdose. This indicator helps determine patients who may have drug seeking habits (i.e. doctor shopping ). The rate of MPE s in county were lower than the state in 2014 and had no patients with MPE s during 2015-2016. Compared to all other counties, County ranked in the lower half. West Virginia Board of Pharmacy October 2017 6

County Indicator 4: Percent of patients prescribed long-acting/extended release opioids among opioid-naïve patients. This indicator represents the percent of patients with no prescribed opioid prescriptions in the previous 60 days who were prescribed at least one long acting/extended release (LA/ER) opioid, among all patients with LA/ER opioid prescriptions. It includes all opioid prescriptions that are classified as either II, III or IV. Figure 11. Percent of Patients 50 40 30 20 10 0 Percent of Patients Prescribed Long-Acting/Extended Release Opioids among Opioid-naïve Patients, County and, 2014-2016 37.4 39.0 16.3 14.5 9.4 11.2 County Rank 53 55 54 This indicator is important to understand because it provides information about individuals that are not accustomed to opioid medications, which may potentially increase the risk of opioid dependence and abuse. CDC opioid prescribing guidelines recommend using immediate release (IR) opioids before taking LA/ER. County had a slightly higher percent of patients than the state during 2014-2016 and ranked near the bottom compared to all other counties. West Virginia Board of Pharmacy October 2017 7

County Indicator 5: Percent of patient prescription days with overlapping opioid prescriptions. This indicator shows the percent of days where more than one prescribed opioid prescriptions during the same time-period where dispensed, among all prescription days. It includes all opioid prescriptions that are classified as either II, III or IV. Figure 12. Percent of Patients Prescribed Days Overlap Between Opioid Analgesics, County and, 2014-2016 Percent 16 14 12 10 8 6 4 2 0 12.0 11.2 11.3 11.1 10.7 10.6 County 19 16 16 Rank This indicator represents the patients who may potentially be using their opioid prescriptions not as prescribed or may show areas where drug diversion is occurring. Drug diversion is the process of transferring controlled substances that was prescribed legally to another person for illicit use. According to the National Survey on Drug Use and Health (NSDUH), over 50% of people who misused a prescription painkiller got them from a friend or relative for free, and 22% got them from a doctor 2. Using multiple opioid prescriptions during the same time-period increased the risk for drug dependency and overdose. It is important to understand this because a considerable number of drug overdose deaths included more than one opioid. County had slightly a higher percent of prescription overlap compared to the state during 2014-2016 and was ranked in the upper half. 2 https://www.samhsa.gov/atod/opioids West Virginia Board of Pharmacy October 2017 8

County Indicator 6: Percent of patient prescriptions days with overlapping opioid and benzodiazepine prescriptions. This indicator represents the percent of patients who have an opioid and a benzodiazepine (i.e. Lorazepam, Diazepam) prescription on the same day among all opioid prescriptions days. It includes all opioid prescriptions that are classified as either II, III or IV. Figure 13. Percent of Patients Prescribed Opioid Days that Overlap with Benzodiazepine Prescriptions, County and, 2014-2016 Percent 40 35 30 25 20 15 10 5 0 30.6 24.4 26.9 25.3 20.7 20.5 County 37 40 34 Rank This indicator is important because it shows areas in the state where patients are using both opioids and benzodiazepine drugs. Taking an opioid with a benzodiazepine increases the risk for drug overdose and death, as both classes of medication depress the central nervous system. County had a lower percent of days where there was an overlapping opioid and benzodiazepine prescription than the state and ranked in the lower half compared to other counties. West Virginia Board of Pharmacy October 2017 9

County Percent of County with a controlled substance prescription 29.7% Percent of County with an opioid prescription 21.0% Percent of County with a benzodiazepine prescription 8.2% For more information regarding this county profile or the West Virginia Controlled Substance Monitoring Program (CSMP), please see contact information below. Contact Information: Mike Goff, CSMP Administrator Phone: (304) 558-8411 E-mail: Michael.L.Goff@wv.gov Nathan Wood, CSMP Epidemiologist Phone: (304) 356-4359 E-mail: Nathan.G.Wood@wv.gov Mohsin Mahar, CSMP Data Analyst Phone: (304) 356-4428 E-mail: Mohsin.A.Mahar@wv.gov West Virginia Board of Pharmacy October 2017 10